iShares Biotechnology ETF (NASDAQ:IBB) Shares Purchased by Kovack Advisors Inc.

Kovack Advisors Inc. increased its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 5.3% in the 4th quarter, Holdings Channel reports. The firm owned 2,060 shares of the financial services provider’s stock after purchasing an additional 104 shares during the period. Kovack Advisors Inc.’s holdings in iShares Biotechnology ETF were worth $272,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of IBB. Pinnacle Associates Ltd. raised its position in shares of iShares Biotechnology ETF by 2.7% during the 3rd quarter. Pinnacle Associates Ltd. now owns 13,556 shares of the financial services provider’s stock worth $1,842,000 after purchasing an additional 359 shares during the last quarter. US Bancorp DE raised its position in shares of iShares Biotechnology ETF by 2.8% during the 3rd quarter. US Bancorp DE now owns 14,028 shares of the financial services provider’s stock worth $2,042,000 after purchasing an additional 378 shares during the last quarter. Farther Finance Advisors LLC raised its position in shares of iShares Biotechnology ETF by 64.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 5,770 shares of the financial services provider’s stock worth $840,000 after purchasing an additional 2,264 shares during the last quarter. Chicago Partners Investment Group LLC raised its position in shares of iShares Biotechnology ETF by 45.8% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 3,689 shares of the financial services provider’s stock worth $524,000 after purchasing an additional 1,159 shares during the last quarter. Finally, Realta Investment Advisors raised its position in shares of iShares Biotechnology ETF by 306.8% during the 3rd quarter. Realta Investment Advisors now owns 4,117 shares of the financial services provider’s stock worth $600,000 after purchasing an additional 3,105 shares during the last quarter. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Up 1.1 %

IBB opened at $137.03 on Friday. iShares Biotechnology ETF has a twelve month low of $123.60 and a twelve month high of $150.57. The company has a 50-day moving average price of $135.91 and a 200 day moving average price of $140.62. The company has a market cap of $6.33 billion, a PE ratio of 24.52 and a beta of 0.77.

iShares Biotechnology ETF Cuts Dividend

The firm also recently disclosed a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were issued a $0.0624 dividend. The ex-dividend date of this dividend was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.